Cyclerion Therapeutics (NASDAQ:CYCN) Trading Up 7.2% – Here’s Why

Shares of Cyclerion Therapeutics, Inc. (NASDAQ:CYCN) rose 7.2% on Thursday . The company traded as high as $1.99 and last traded at $1.93. Approximately 878,164 shares changed hands during trading, a decline of 80% from the average daily volume of 4,346,326 shares. The stock had previously closed at $1.80.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reissued a “sell (d-)” rating on shares of Cyclerion Therapeutics in a research report on Monday, December 22nd. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the company has an average rating of “Sell”.

Cyclerion Therapeutics Stock Performance

The company has a 50 day moving average of $1.54 and a two-hundred day moving average of $2.25. The stock has a market capitalization of $7.58 million, a PE ratio of -2.57 and a beta of 0.96.

Cyclerion Therapeutics (NASDAQ:CYCN) last released its earnings results on Thursday, October 30th. The company reported ($0.30) earnings per share for the quarter. Cyclerion Therapeutics had a negative return on equity of 24.61% and a negative net margin of 77.02%.The company had revenue of $0.88 million for the quarter.

Institutional Investors Weigh In On Cyclerion Therapeutics

A hedge fund recently bought a new stake in Cyclerion Therapeutics stock. Two Sigma Investments LP acquired a new stake in Cyclerion Therapeutics, Inc. (NASDAQ:CYCN) in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund acquired 13,293 shares of the company’s stock, valued at approximately $31,000. Two Sigma Investments LP owned 0.40% of Cyclerion Therapeutics as of its most recent SEC filing. Hedge funds and other institutional investors own 75.62% of the company’s stock.

About Cyclerion Therapeutics

Cyclerion Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of inhibitors and stimulators of soluble guanylate cyclase (sGC), an intracellular enzyme that plays a critical role in the regulation of vascular tone, cellular proliferation and inflammation. By targeting the nitric oxide (NO)–sGC–cyclic guanosine monophosphate (cGMP) signaling pathway, Cyclerion aims to address a range of cardiometabolic, cardiovascular, pulmonary and neurological disorders with significant unmet medical need.

The company’s lead program, praliciguat, is an oral sGC stimulator investigated for indications such as diabetic nephropathy, metabolic syndrome and heart failure with preserved ejection fraction.